COMMUNIQUÉS West-GlobeNewswire

Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

01/05/2024 - 14:30

Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker [...]

Cepham’s Luteye Centers on Cellular Senescence to Protect Aging Eyes

01/05/2024 - 14:30

SOMERSET, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- In alignment with Healthy Vision Month in May, Cepham , a leader in Ayurvedic nutraceutical ingredients, announces the launch of Luteye, a branded ingredient that [...]

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

01/05/2024 - 14:30

Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end Carlsbad, CA, May 01, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“ [...]

Alpha Tau to Participate in May Investor Conferences

01/05/2024 - 14:30

JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that [...]

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split

01/05/2024 - 14:30

WOBURN, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that it will effect a 1-for-24 reverse stock split [...]

Bionet America, Inc. Launches New Brio XVet Multiparameter Veterinary Monitors

01/05/2024 - 14:10

Next-generation surgical monitors enhance safety and convenience for veterinary care TUSTIN, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Bionet America, Inc. today announced the launch of the new Brio XVet series, a [...]

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

01/05/2024 - 14:05

Acquire cell therapy manufacturing facility with clinical and commercial capabilities Further ExacTcell platform for additional clinical trials based on successful completion of POC Highlight full year financial results [...]

electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024

01/05/2024 - 14:04

ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first [...]

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

01/05/2024 - 14:01

BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership [...]

Goodness Growth Provides CREAM & Fire Updates

01/05/2024 - 14:01

– Josh Rosen to shed Interim title and become Chief Executive Officer; Company provides other key personnel updates – – Company receives a short-term extension of the maturity date on its credit facility – – Company [...]

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

01/05/2024 - 14:00

Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease Akari Therapeutics announces leadership changes in separate Akari [...]

Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story

01/05/2024 - 14:00

Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree ® The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled in just two years [...]

Creyon Bio and Cajal Neuroscience Announce Partnership to Develop Oligonucleotide-Based Medicines for Neurodegenerative Diseases

01/05/2024 - 14:00

SAN DIEGO and RESEARCH TRIANGLE PARK, N.C. and SEATTLE, May 01, 2024 (GLOBE NEWSWIRE) -- Creyon Bio , Inc. ("Creyon"), a drug development company that engineers Oligonucleotide-Based Medicines (OBMs) with industry [...]

The Canadian Dermatology Association urges Canadians to protect themselves from skin cancer this summer

01/05/2024 - 14:00

OTTAWA, May 01, 2024 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) has launched its annual month-long Sun Awareness Campaign. This year is focused on protecting children and adolescents; the campaign [...]

L’Association canadienne de dermatologie incite les Canadiens à se prémunir contre les cancers de la peau cet été

01/05/2024 - 14:00

OTTAWA, 01 mai 2024 (GLOBE NEWSWIRE) -- L’Association canadienne de dermatologie (ACD) lance sa campagne annuelle Prudence au soleil, d’une durée d’un mois. Cette année, l’accent sera mis sur la protection des enfants [...]

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

01/05/2024 - 14:00

DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a [...]

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

01/05/2024 - 14:00

Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“ [...]

Auron Announces Oral Presentation on Preclinical Data from Proprietary AURIGIN™ Platform at the AI in Biomedicine Keystone Symposia

01/05/2024 - 14:00

NEWTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics , a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, [...]

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

01/05/2024 - 14:00

- CX-904 (masked EGFRxCD3 Probody ® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study - - Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8 th - SOUTH [...]